Ratings for Henry Schein (NASDAQ:HSIC) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.5, with a high estimate of $92.00 and a low estimate of $80.00. Holding firm without variation, the current average remains at the previous average price target.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Henry Schein's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Petusky | Barrington Research | Maintains | Outperform | $92.00 | $92.00 |
| Jason Bednar | Piper Sandler | Maintains | Overweight | $86.00 | $86.00 |
| Michael Petusky | Barrington Research | Raises | Outperform | $92.00 | $90.00 |
| Kevin Caliendo | UBS | Lowers | Neutral | $80.00 | $82.00 |
Key Insights:
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Henry Schein's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Henry Schein analyst ratings.
Unveiling the Story Behind Henry Schein
Henry Schein's Economic Impact: An Analysis
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Henry Schein's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.66% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Henry Schein's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.56%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Henry Schein's ROA stands out, surpassing industry averages. With an impressive ROA of 0.9%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
